Methydur (methydur sustained release capsules) / Durect, Orient Europharma - LARVOL DELTA

A Counting Stroop Functional Magnetic Resonance Imaging Study on the Effects of ORADUR-Methylphenidate in Drug-Naive Children with Attention-Deficit/Hyperactivity Disorder. (PubMed, J Child Adolesc Psychopharmacol) - P3 | "Activities of these brain regions might be biomarkers for the treatment effectiveness of methylphenidate for ADHD. Clinical Trials Registration: ClinicalTrials.gov number, NCT02450890."

Journal • MRI • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD (clinicaltrials.gov) - P3; N=64; Completed; Sponsor: Orient Pharma Co., Ltd.; Recruiting ➔ Completed

Clinical • Trial completion • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD (clinicaltrials.gov) - P3; N=114; Completed; Sponsor: Orient Pharma Co., Ltd.; Active, not recruiting ➔ Completed

Clinical • Trial completion • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. (PubMed, J Child Adolesc Psychopharmacol) - P3 | "Once-daily ORADUR-MPH is an effective, well-tolerable, and safe treatment for children and adolescents with ADHD. ClinicalTrials.gov number, NCT02450890."

Clinical • Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Mental Retardation • Psychiatry

Therapeutic Effects of the 8-Week ORADUR-Methylphenidate on Drug-Nave Children With Attention-Deficit/Hyperactivity Disorder: A Counting Stroop Functional MRI Study (ACNP 2019) - "Treatment with ORADUR®-Methylphenidate may increase the brain activity in the dACC, rDLPFC, and rIFG corresponding to improving focused attention, impulsivity, and inhibition control in drug-naïve children with ADHD. These brain regions might play a role as biological markers for the treatment effectiveness of methylphenidate."

Clinical